CLAIMS

1. Use of punicalagin, or a pharmaceutically acceptable salt, solvate, or hydrate, thereof, in the manufacture of a medicament for the treatment or prevention of a cognitive disorder, a neurodegenerative disorder, an amyloidosis-related condition, Alzheimer's disease, dementia, ALS, Huntington's disease, Parkinson's disease, or Down syndrome, wherein the medicament is to be administered to a human; and wherein the therapeutically effective amount is between 100 mg and 2,500 mg per day.

2. The use of claim 1, wherein the medicament treats or prevents Alzheimer's disease.

3. The use of claim 1, wherein the medicament treats or prevents a cognitive disorder.

4. The use of claim 1, wherein the medicament treats or prevents a neurodegenerative disorder.

5. The use of claim 1, wherein the medicament treats or prevents an amyloidosis-related condition.

6. The use of claim 1, wherein the medicament treats or prevents dementia.

7. The use of claim 1, wherein the medicament treats or prevents ALS.

8. The use of claim 1, wherein the medicament treats or prevents Huntington's disease.

9. The use of claim 1, wherein the medicament treats or prevents Parkinson's disease.

10. The use of claim 1, wherein the medicament treats or prevents Down syndrome.

11. The use of claim 2, wherein the medicament treats Alzheimer's disease.

12. The use of claim 3, wherein the medicament treats a cognitive disorder.

13. The use of claim 4, wherein the medicament treats a neurodegenerative disorder.

14. The use of claim 5, wherein the medicament treats an amyloidosis-related condition.

15. The use of claim 6, wherein the medicament treats dementia.

16. The use of claim 7, wherein the medicament treats ALS.

17. The use of claim 8, wherein the medicament treats Huntington's disease.

18. The use of claim 9, wherein the medicament treats Parkinson’s disease.

19. The use of claim 10, wherein the medicament treats Down syndrome.

20. The use of claim 2, wherein the medicament prevents Alzheimer’s disease.

21. The use of claim 3, wherein the medicament prevents a cognitive disorder.

22. The use of claim 4, wherein the medicament prevents a neurodegenerative disorder.

23. The use of claim 5, wherein the medicament prevents an amyloidosis-related condition.

24. The use of claim 6, wherein the medicament prevents dementia.

25. The use of claim 7, wherein the medicament prevents ALS.

26. The use of claim 8, wherein the medicament prevents Huntington’s disease.

27. The use of claim 9, wherein the medicament prevents Parkinson’s disease.

28. The use of claim 10, wherein the medicament prevents Down syndrome.

29. The use of claim 6, wherein said dementia is age-related.

30. The use of claim 1, wherein the memory of the human is improved.

31. The use of claim 30, wherein the improvement in memory is an improvement in at least one measure selected from the group consisting of an improvement in short-term memory, long-term memory, memory consolidation, procedural memory and declarative memory.

32. The use of claim 30, wherein the memory is long-term memory.

33. The use of claim 30, wherein the memory is short-term memory.

34. The use of claim 1, wherein the memory of the human is maintained.

35. The use of claim 34, wherein the memory is long-term memory.

36. The use of claim 34, wherein the memory is short-term memory.

37. The use of claim 1, wherein a neuron or plurality of neurons in said human are protected.

38. The use of claim 1, wherein the general cognition of the human is improved.

39. The use of claim 1, wherein the general cognition of the human is maintained.

40. The use of claim 1, wherein the therapeutically effective amount is between 250 mg and 1,000 mg per day.

41. The use of claim 1, wherein the therapeutically effective amount is between 250 mg and 500 mg per day.

42. The use of claim 1, wherein the therapeutically effective amount is between 500 mg and 750 mg per day.

43. Use of punicalagin, or a pharmaceutically acceptable salt, solvate, or hydrate, thereof, in the manufacture of a medicament to be administered to a human, wherein the medicament treats or prevents ALS, Huntington's disease, Parkinson's disease, or Down syndrome.

44. The use of claim 43, wherein the medicament treats ALS.

45. The use of claim 43, wherein the medicament treats Huntington's disease.

46. The use of claim 43, wherein the medicament treats Parkinson's disease.

47. The use of claim 43, wherein the medicament treats Down syndrome.

48. The use of claim 43, wherein the medicament prevents ALS.

49. The use of claim 43, wherein the medicament prevents Huntington's disease.

50. The use of claim 43, wherein the medicament prevents Parkinson's disease.

51. The use of claim 43, wherein the medicament prevents Down syndrome.